Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Vistagen Therapeutics Inc (NQ: VTGN ) 3.070 +0.010 (+0.33%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Vistagen Therapeutics Inc < Previous 1 2 3 4 5 6 Next > TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Joint Ceremony to Ring Nasdaq Closing Bell in Honor of World Mental Health Day October 09, 2024 Via Investor Brand Network Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day October 09, 2024 From Vistagen Via Business Wire Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder September 23, 2024 From Vistagen Via Business Wire BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases Q1 2025 Financial, Corporate Report August 14, 2024 Via Investor Brand Network Vistagen Reports Fiscal Year 2025 First Quarter Financial Results and Corporate Update August 13, 2024 From Vistagen Via Business Wire InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules Release of Q1 2025 Results, Conference Call August 06, 2024 Via Investor Brand Network Vistagen to Report Fiscal Year 2025 First Quarter Results and Host Corporate Update Conference Call on August 13, 2024 August 06, 2024 From Vistagen Via Business Wire InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Awarded New Patents from Four Countries to Broaden Global PH80 IP Portfolio July 09, 2024 Via Investor Brand Network Topics Intellectual Property Exposures Intellectual Property Vistagen Broadens PH80 Global Intellectual Property Portfolio with New Patents for the Treatment of Migraine July 09, 2024 From Vistagen Via Business Wire InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Receives Mental Health America’s Highest Honor June 27, 2024 Via Investor Brand Network Vistagen Awarded Mental Health America’s Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year June 27, 2024 From Vistagen Via Business Wire TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Releases FY 2024 Financial Report, Corporate Update June 12, 2024 Via Investor Brand Network Vistagen Reports Fiscal Year 2024 Financial Results and Provides Corporate Update June 11, 2024 From Vistagen Via Business Wire BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) Schedules FY 2024 Financial Results Report, Conference Call June 07, 2024 Via Investor Brand Network Vistagen to Report Fiscal Year 2024 Financial Results and Host Corporate Update Conference Call on June 11, 2024 June 07, 2024 From Vistagen Via Business Wire TinyGemsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) CEO to Present at Jefferies Global Healthcare Conference May 29, 2024 Via Investor Brand Network Vistagen to Present at the Jefferies Global Healthcare Conference May 29, 2024 From Vistagen Via Business Wire BioMedNewsBreaks — Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present Posters at Upcoming ASCP Conference May 23, 2024 Via Investor Brand Network Vistagen to Present at the 2024 American Society of Clinical Psychopharmacology (ASCP) Conference May 23, 2024 From Vistagen Via Business Wire InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at Upcoming RBC Capital Markets Global Healthcare Conference May 07, 2024 Via Investor Brand Network Vistagen to Present at the 2024 RBC Capital Markets Global Healthcare Conference May 07, 2024 From Vistagen Via Business Wire InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Reports Positive PH15 Data from Pilot Study Showing Psychomotor Impairment Improvement April 25, 2024 Via Investor Brand Network Vistagen Announces Positive Results from Phase 2A Pilot Study of PH15 for Improvement of Psychomotor Impairment Caused by Mental Fatigue April 25, 2024 From Vistagen Via Business Wire InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) Announces Participation at Upcoming Anxiety and Depression Association Conference April 09, 2024 Via Investor Brand Network Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference April 09, 2024 From Vistagen Via Business Wire InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Appointment of New VP of Translational Medicine April 01, 2024 Via Investor Brand Network Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2 April 01, 2024 From Vistagen Via Business Wire InvestorNewsBreaks — Vistagen Therapeutics Inc.’s (NASDAQ: VTGN) Announces Participation at Upcoming Stifel 2024 Virtual CNS Days March 11, 2024 Via Investor Brand Network Vistagen to Present at Stifel 2024 Virtual CNS Days March 11, 2024 From Vistagen Via Business Wire InvestorNewsBreaks – Vistagen Therapeutics Inc. (NASDAQ: VTGN) to Present at TD Cowen Conference February 28, 2024 Via Investor Brand Network < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.